Combination of Rituximab and NK Immunotherapy for B Lymphoma

NCT02843061 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma Recurrent

Interventions

DRUG: Rituximab
BIOLOGICAL: NK immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou

Collaborators

[object Object]